BDSX — Biodesix Income Statement
0.000.00%
Last trade - 00:00- $78.68m
- $88.87m
- $71.32m
- 40
- 34
- 27
- 25
Annual income statement for Biodesix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 45.6 | 54.5 | 38.2 | 49.1 | 71.3 |
| Cost of Revenue | |||||
| Gross Profit | 23.6 | 24 | 24.1 | 36.1 | 55.8 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 68.5 | 93.1 | 95.8 | 90.4 | 106 |
| Operating Profit | -22.9 | -38.6 | -57.6 | -41.3 | -34.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31.4 | -43.2 | -65.4 | -52.1 | -42.9 |
| Net Income After Taxes | -31.4 | -43.2 | -65.4 | -52.1 | -42.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -31.4 | -43.2 | -65.4 | -52.1 | -42.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -31.4 | -43.2 | -65.4 | -52.1 | -42.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.15 | -1.66 | -1.39 | -0.635 | -0.327 |